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Abstract
Purpose Chronic asthenia (CA) is complained by some pa-
tients that have undergone thyroid surgery. We evaluate its
impact in patients undergoing unilateral or bilateral thyroidec-
tomy, the trend during a 1-year follow-up, and the possible
risk factors.
Methods A prospective, cohort study was carried out on 263
patients scheduled for thyroidectomy from 2012 and 2014.
Exclusion criteria were as follows: Graves’ disease, malignan-
cies requiring radioiodine therapy, post-surgical hypoparathy-
roidism, laryngeal nerve palsy, abnormal pre- and post-
operative thyroid hormone levels, and BMI outside the normal
range. Demographics; smoking and alcoholism addiction; car-
diac, pulmonary, renal, and hepatic failure; diabetes; anxiety;
and depression were recorded. The Brief Fatigue Inventory
(BFI) was used to evaluate CA and its possible association
with these comorbidities 6 and 12months after thyroidectomy.
Results One hundred seventy-seven patients underwent total
thyroidectomy (TT), 54 hemithyroidectomy (HT). Thirty-two
patients were not recorded because of the onset of exclusion
criteria. In the 6 months after thyroidectomy, in the TT group,
64 patients (36.16%) reported an impairment in the BFI score
and only 1 in the TL group. ThemeanBFI score changed from
1.663(±1.191) to 2.16 (±11.148) in the TT group, from 1.584
(±1.371) to 1.171 (±1.093) in the TL group (p < 0.001). No
further significant variations in BFI were reported 1 year after
surgery.
Conclusions CA worsened after TT, but not after HT. Apart
from operative procedure itself, no other risk factor was found
be significantly associated with post-thyroidectomy asthenia.
Further investigation is needed to determine the causes of CA.
Keywords Total thyroidectomy . Hemithyroidectomy .
Chronic asthenia . Fatigue
Introduction
Total thyroidectomy (TT) was previously considered the treat-
ment of choice for benign diseases andmalignancies [1–5]. As
a result, this surgical procedure has widespread indications at
our institution [6, 7]. Several studies have examined patient
quality of life (QoL) related to the thyroid disorders and eval-
uated this aspect before and after treatment. The majority of
studies investigated the correlation between QoL and hor-
mone changes [8–10]. One study highlighted the psycholog-
ical changes rather than appearance or worsening of the tired-
ness or asthenia [11]. Another study showed the advantages of
thyroidectomy in reducing post-operative fatigue by evaluat-
ing a cohort of patients with various hormone levels [8]. A
recent study [12] reported that TT is frequently accompanied
by chronic low-moderate asthenia. The asthenia can result in
impaired QoL due to feelings of tiredness and a reduced abil-
ity to perform physical or mental tasks. These symptoms have
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not been evaluated in specific clinical trials despite being
widely suspected and commonly observed.
The aim of the present study is to evaluate the real impact
of post-thyroidectomy chronic asthenia (PTCA) in patients
undergoing unilateral or bilateral excision of the thyroid
gland. We also evaluated the trends after a 1-year post-opera-
tive follow-up period.
In this study, we assessed whether PTCA is induced or
worsened in the presence of specific habits (smoking, alco-
hol), chronic diseases (cardiac, pulmonary, hepatic, renal, met-
abolic), or mental disorders such as anxiety or depression.
Materials and methods
Patient population
This study involved 263 consecutive consenting patients from
a homogeneous area (three western areas of Sicily: Palermo,
Trapani, Agrigento) scheduled for thyroidectomy at the Unit
of General and Emergency Surgery of BPoliclinico Paolo
Giaccone^ University Hospital, in Palermo from January
2012 to December 2014. We included all patients with the
benign nodular thyroid disease euthyroid at the time of enroll-
ment and throughout the study. All patients had a BMI within
the normal range for Caucasians based on WHO criteria [13].
The patients were traceable during all the fixed stages of the
follow-up (pre-operative, 6 months, and 1 year after surgery).
Exclusion criteria
The following exclusion criteria were used in this study: thy-
roid carcinoma (except low-risk papillary microcarcinoma)
(seven patients), Graves’ disease due to its negative impact
on health-related QoL [14, 15], chronic anemia (including
thalassemia), chronic disease (cardiac, pulmonary, hepatic, re-
nal) in advanced stage, type 1 diabetes mellitus or type 2
diabetes requiring insulin treatment for control, inflammatory
bowel diseases, hyperparathyroidism, functional adrenal dis-
eases, personal history of cancer, and all diseases interfering
with performance status. Chronic diseases were evaluated in
all study periods. If a chronic disease worsened during the
follow-up period, the patients were excluded (two patients).
We used the New York Heart Association (NYHA) criteria to
evaluate and measure chronic heart failure [16], and the pa-
tients in class III or IV were excluded. Chronic respiratory
failure severity was evaluated in accordance with GOLD
criteria [17]. The patients classified as level II or III were
excluded. We also excluded patients with hepatic failure in
Child and Pugh C-class [18] and those with stage III (or more
advanced) chronic renal failure in accordance with KDOQI
guidelines [19]. The diagnosis of diabetes mellitus was
established in accordance with the American Diabetes
Association criteria [20]. All mental disorders were evaluated
in the pre-operative period and at the 6- and 12-month follow-
up evaluations. Anxiety was evaluated using a common seven-
item self-administered questionnaire (available online) [21] in-
vestigating generalized anxiety disorders (GAD-7). The patients
with a score ≥10 in one of the three follow-up steps were exclud-
ed from the study (four patients). The Hamilton Depression
Rating Scale (HAM-D) [22] was used to exclude patients suffer-
ing from depression. The patients with more than moderate de-
pression (score ≥19) were also excluded (one patient).
Asthenia was assessed and measured by the Brief Fatigue
Inventory (BFI), which is a nine-item visual analog score system
(Fig. 1). This system is reliable and is validated for a wide range
of diseases (both benign and malignant) [23, 24]. The tool inves-
tigates the current level of asthenia in patients for the last 24 h and
any interference with general activity, work, and relationships
with other people [12, 24]. We obtained permission to use this
tool (Italian version) online. The results of the questionnaire are
used to classify asthenia as mild (score <3), moderate (scores
between 4 and 6), or severe (scores between 7 and 10). The
patients with severe asthenia were previously excluded.
We also excluded all patients that complained post-operative
complications: inferior laryngeal nerve palsy (three patients), per-
sistent hypoparathyroidism (two patients). Seven patients did not
meet the inclusion criteria concerning the BMI. Finally, we lost
two patients during the follow-up.
Indications for surgery
The recommended surgical procedure (unilateral or bilateral
resection of thyroid gland) was consistent with our internal
protocols and was chosen definitively on the basis of informed
consent. These protocols indicated resection extent in accor-
dance with the Bethesda system for reporting thyroid cytopa-
thology [25]. The patients with unilateral benign cytology
diagnosis, indeterminate, or suspicious lesions were offered
hemithyroidectomy (HT). The patients with bilateral nodules
were offered total thyroidectomy (TT). After the cytology re-
sults were obtained, the patients were informed of the risks
and advantages of each surgical procedure with respect to
potential complications and recurrence rate. The resection ex-
tent was finally chosen in accordance with their wishes. The
surgical procedure was a total extracapsular, unilateral or bi-
lateral resection of thyroid gland with systematic identification
of the inferior laryngeal nerve and the parathyroid glands. A
complete removal of the isthmus of the gland was always
achieved during the thyroid lobectomy.
Post-operative treatment
The blood calcium levels were measured on the first
post-operative day in accordance with institutional protocols.
If the calcium value was less than 8 mg, then an empirical
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daily oral supplementation of calcium (1000–4000 mg, in ac-
cordance with needs) and calcitriol (0.50–1.25 mcg) was ad-
ministered for progressive low values of calcemia. The sup-
plementation was gradually reduced in outpatient manage-
ment as calcium values improved. Levothyroxine was system-
atically prescribed to optimize supplementary (for the patients
in the HT group) or substitutive (for the TT group) treatment
at discharge on the first or second post-operative day. The
treatment adjustments weremade during post-operative examina-
tions. The thyroid-stimulating hormone (TSH) value was main-
tained at approximately 1 mIU/L. If the TSH value was lower
than 0.5 mIU/L or higher than 1.9 mIU/L, then the L-thyroxine
dosage was adjusted to approach the target values throughout
follow-up. If patients showed TSH values ≤0.4 or >4 mIU/L at
any stage of the follow-up, then they were excluded from the
study (four patients). Table 1 shows the TSHmean values during
the three periods in both groups. A histological examination con-
firmed the complete removal of the thyroid tissue in all cases, the
absence of a cancer >1 cm, and the nature of the lesion.
Statistical analysis We used two-way ANOVA to analyze de-
pression and asthenia because these variables were surveyed
three times. The test was used to verify whether the two groups
differ regarding surgical technique (TT, HT) or survey time (pre-
operative, 6 months after the thyroidectomy, 1 year after the
thyroidectomy). Patient anxiety was analyzed as a dichotomous
variable. Anxiety was evaluated with theMantel-Haenszel test to
verify the hypothesis of equality between the odds ratios (ORs)
for the three results in the TTandHT patients. Amultiple logistic
regression for dichotomous dummy variables was used to ana-
lyze the effects of other variables relative to the BFI (evaluated
three times). The analysis was conducted using IDE RStudio
(version 0.98.945, RStudio, Boston, MA, USA) with R software
(3.1.0, 2014-04-10).
Results
Excluding the 32 patients from the definitive record, we then
analyzed 231 patients, which were divided into the TT group
(177 patients) treated with surgery for a multinodular goiter,
euthyroid or toxic, ± Hashimoto’s thyroiditis or the HT group
(54 patients) that had undergone surgery for a single nontoxic
nodule (compressive or needing bioptic examination), or
Questionario Breve Per La Valutazione Della Stanchezza Cronica
N°STUDIO ____________ N°OSPEDALE ____________
Data: ______/ ______/ ______ Ora: _________________
Nome: ___________________ _____________________ ____________________
Cognome Nome Iniziale del secondo nome
Nel corso della vita, la maggior parte di noi attraversa periodi in cui si sente molto
stanco/a o affaticato/a. Si è sentito/a più stanco/a o affaticato/a 
del solito nell’ultima settimana (7 giorni)? Sì No
1. Valuti il suo affaticamento (stanchezza) facendo una crocetta sul numero che
esprime meglio il suo grado di affaticamento in QUESTO MOMENTO. 
0 1 2 3 4 5 6 7 8 9 10
Nessun
affaticamento
Il peggior affaticamento 
che si possa immaginare
2. Valuti il suo affaticamento (stanchezza) facendo una crocetta sul numero che
esprime meglio il suo ABITUALE grado di affaticamento nelle ultime 24 ore.
0 1 2 3 4 5 6 7 8 9 10
Nessun
affaticamento
Il peggior affaticamento 
che si possa immaginare
3. Valuti il suo affaticamento (stanchezza) facendo una crocetta sul numero che
esprime meglio il suo PEGGIORE grado di affaticamento nelle ultime 24 ore. 
0 1 2 3 4 5 6 7 8 9 10
Nessun
affaticamento
Il peggior affaticamento 
che si possa immaginare
4. Faccia una crocetta sul numero che meglio descrive quanto, nelle ultime 24
ore, l’affaticamento ha interferito con:
A. Attività In Genere
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
B. Umore
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
C. Capacità di camminare
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
D. Lavoro normale (comprende sia il lavoro fuori casa che le attività quotidiane in casa)
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
E. Rapporti con altre persone
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
F. Capacità di divertirsi
0 1 2 3 4 5 6 7 8 9 10
Non ha interferito Ha interferito completamente
Copyright 1999
The University of Texas M. D. Anderson Cancer Center
All rights reserved.
Brief Fatigue Inventory
STUDY ID# ____________ HOSPITAL# ____________
Date: ______/ ______/ ______ Time: _________________
Name: ___________________ ______________________ _______________
Last First Middle Initial
Throughout our lives, most of us have times when we feel very tired or fatigued.
Have you felt unusually tired or fatigued in the last week? Yes No
1. Please rate your fatigue (weariness, tiredness) by circling the one number 
that best describes your fatigue right NOW.
0 1 2 3 4 5 6 7 8 9 10
No
Fatigue
As bad as
you can imagine
2. Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your USUAL level of fatigue during past 24 hours.
0 1 2 3 4 5 6 7 8 9 10
No
Fatigue
As bad as
you can imagine
3. Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your WORST level of fatigue during past 24 hours.
0 1 2 3 4 5 6 7 8 9 10
No
Fatigue
As bad as
you can imagine
4. Circle the one number that describes how, during the past 24 hours,
fatigue has interfered with your:
A. General Activity
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
B. Mood
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
C. Walking ability
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
D. Normal work (includes both work outside the home and daily chores)
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
E. Relations with other people
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
F. Enjoyment of life
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
Copyright 1999
The University of Texas M. D. Anderson Cancer Center
All rights reserved.
a b
Fig. 1 Questionnaire used for asthenia evaluation: Italian version (a) is a psychometrically and linguistically validated version obtained from BMD
Anderson Assessment Tool Distribution^; we submitted this version to our patients; English version (b)
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Plummer’s disease. Table 2 shows the demographic and clin-
ical data for both patient groups. The groups were balanced
with respect to patient gender. However, the patient age in the
TT group was slightly higher due to the higher concentration
of young patients in the HT group. Other variables that were
not well-balanced between two groups were hepatic disease
and smoking. It is possible that multinodular goiter is more
frequent in the context of chronic hepatitis and its evolutions.
The reason for a relatively higher prevalence of smoker
subjects in the HT group is not clear. Table 3 analyzes the
balance of anxiety, depression, and fatigue in the two groups
at the three observation time points using ANOVA. The anx-
iety was similar in the TT and HT groups in the three periods
of observation. However, the prevalence of depression was
different based on value medians. The values did not change
during the follow-up or improved similarly in each group and
were not statistically significant. Asthenia was similar in the
two groups at the pre-operative evaluation but changed signif-
icantly in the next two post-operative periods. We analyzed
the impact of each variable including the extent of surgical
resection on post-operative asthenia once the initial differ-
ences between the two groups had been evaluated with respect
to habits and comorbidities. The results of our multivariate
logistic regression analysis are summarized in Table 4. The
data indicate that only the variable Bsurgical technique^ (TT,
HT) determines significant changes in the onset or worsening
of the asthenia. The HT group showed that the asthenia did not
appear or worsen during the follow-up. Conversely, the asthe-
nia improved in several cases and this change was clear when
comparing the pre-operative results with the 6-month follow-
up. The findings are represented in the box-plot graphs
(Fig. 2a, b) and show the trend of the CA over time in TT
and HT groups.
Table 1 Enrolled patients’ TSH mean values (mIU/L) during the study
TSH values (mean) p values
Pre-
operative
6 months after
surgery
1 year after
surgery
TT 1.39 ± 0,32 1.29 ± 0.41 1.47 ± 0.44 0.22a
0.36b
HT 1.19 ± 0.44 1.39 ± 0.45 1.54 ± 0.6 0.51a
0.45b
p
value
0.44 0.29 0.36
a Pre-operative TSH values vs 6 months after surgery TSH values
b Pre-operative TSH values vs 1 year after surgery TSH values
Table 2 Balancement of sex,
age, thyroid disease, habits, and
comorbidities in the two groups
Variables TT HT p value
Gender Male 36 (20.3%) 7 (13%) 0.30
Female 141 (79.7%) 47 (87%)
Age Average (years) 54.50 (13.08) 48.94 (15.62) 0.0094*
Thyroid diseases MNG/single nodule (euthyroid patients) 136 (77%) 38 (70%) 0.43
MNTG/Plummer’s diseasea 17 (10%) 13 (24%) 0.01*
Nodule(s) + Hashimoto’s thyroiditis 24 (13%) 3 (6%) 0.17
Smoking No 141 (79.7%) 35 (65%) 0.039*
Yes 36 (20.3%) 19 (35%)
Alcohol No 171 (96.6%) 54 (100%) 0.34
Yes 6 (3.4%) 0 (0%)
Cardiac disease No 104 (58.8%) 34 (63%) 0.69
Yes 73 (41.2%) 20 (37%)
Pulmonary disease No 155 (87.6%) 47 (87%) 0.99
Yes 22 (12.4%) 7 (13%)
Hepatic disease No 160 (90.4%) 54 (100%) 0.014*
Yes 17 (9.6%) 0 (0%)
Renal disease No 162 (91.5%) 53 (98.1%) 0.13
Yes 15 (8.5%) 1 (1.9%)
Diabetes mellitus No 141 (79.7%) 48 (88.9%) 0.18
Yes 36 (20.3%) 6 (11.1%)
Chronic diseases leading to a functional organ insufficiency such as heart failure (inability of the heart to pump
enough blood to meet the body’s needs), respiratory insufficiency (inability of the lungs to maintain an adequate
gas exchange), liver failure (cirrhosis), renal insufficiency
MNG multinodular goiter, MNTG multinodular toxic goiter
*Differences statistically significant
a Since the Plummer’s disease was a standard indication for hemithyroidectomy, its proportional prevalence in the
HT group resulted statistically significant
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Discussion
TTwas used as a surgical treatment for a wide range of thyroid
diseases including solitary benign nodules [6, 26, 27]. Several
assumptions led to this widely shared behavior. The major rea-
sons included the following: low complication rate associated
with TT (as reported by several authors) [27–29], risk of relapse
after hemithyroidectomy [5, 7], risk of an occult malignancy [30]
that makes follow-up complex, and/or greater difficulty in
performing the revision surgery after thyroid lobectomy.
Several recent studies have emphasized various advantages of
hemithyroidectomy [31, 32] in selected cases of malignancy
[33, 34]. Further observations may reinforce the support of HT
such as voice and swallowing disorders that have been evaluated
in association with TT [35, 36]. However, the data concerning
these complaints after HT are limited [37]. Another important
issue that could modify/influence both surgeon and patient
choice in favor of a surgical option is the assessment of the
QoL after thyroidectomy. Prior studies indicated that surgery
extent does not influence the QoL [38] and the specific symptom
Btiredness^ remains one of the most affected domains [39–41]
after thyroidectomy. It should be noted that in these studies both
TT and HT are considered together. Furthermore, the rate of
unilateral compared to bilateral thyroidectomies in these studies
(34.8, 54, and 53%, respectively) is high. Additionally, Grave’s
disease was not an exclusion criterion. The method used for
evaluating the QoL was the ThyPRO, which is a validated and
standardized questionnaire in which tiredness is assessed once in
a general context of complaints referable to a thyroid disease.
Conversely, theBFI assesses the severity of fatigue and its impact
on daily activities by using nine items that are rated with a 0–10
scale [24]. Thus, it is plausible that the more careful method of
analyzing various aspects of fatigue might result in more precise
and reproducible answers.
A previous study that specifically analyzed the correlation
between chronic asthenia and thyroidectomy found patients
who had undergone TT frequently complained of tiredness or
asthenia in performing physical tasks and mental work [12]. It is
well known that hypothyroidism, hyperthyroidism, and
Hashimoto’s thyroiditis may be associated with chronic asthenia
[39, 42]. However, thyroid surgery itself does not improve QoL
except for specific symptoms such as compression. The same
study demonstrated that total or near-TT led to a lower QoL for
several items including Bphysical functioning,^ Bphysical role,^
and Bvitality^ [43]. In our study, we evaluated the real impact of
chronic asthenia in a cohort of patients undergoing thyroidecto-
my for diseases with limited association to asthenia or tiredness.
Therefore, we excluded cases with Grave’s disease or thyroid
cancer because these patients require particular treatment and
not merely a follow-up exam.We excluded the patients suffering
from general comorbidities (cardiac, pulmonary, hepatic, renal,
metabolic) that could be associated with a severe impairment of
their performance status. Furthermore, when comorbidities were
present, we evaluated the impact in determining or worsening the
chronic asthenia.
Table 3 Analysis of anxiety
(Mantel-Haenszel test),
depression and asthenia (two-way
ANOVA test) in the three periods
of observation
Variables Period T.T. H.T. p value
n (%/SD) n (%/SD)
Anxiety Pre-operative 20 (11.3) 5 (9.3) 0.652
6 months after surgery 14 (7.9) 6 (11.1)
1 year after surgery 12 (6.7) 3 (5.5)
Depression Pre-operative 3.09 (±2.69) 3.03 (±2.53) 0.00021 (group)
6 months after surgery 2.65 (±2.55) 2.01 (±2.09) 0.798 (time)
1 year after surgery 2.73 (±2.97) 1.83 (±1.97)
Asthenia Pre-operative 1.663 (±1.191) 1.584 (±1.371) <0.0001 (group)
6 months after surgery 2.16 (±1.148) 1.171 (±1.093)
1 year after surgery 2.106 (±1.235) 1.021 (±1.08) <0.0001 (time)
Table 4 Factors affecting post-thyroidectomy chronic asthenia
Coefficients Estimate Z value p value
Intercept 0.771 1.076 0.281
Sex −0.865 −1.931 0.053
Age −0.017 −1.212 0.225
Surgical procedure (HT) −3.866 −3.716 0.000203*
Smoking −0.036 −0.036 0.971
Alcohol 0.544 1.269 0.204
Heart disease 0.135 0.350 0.726
Pulmonary disease −0.246 −0.043 0.662
Liver disease 0.665 1.133 0.257
Renal disease 0.765 1.071 0.284
Diabetes disease 0.349 0.666 0.505
Anxiety −0.564 −1.014 0.310
Depression −0.093 −1.332 0.182
The position of empirical values in theoretical distribution is used to
calculate the p value
Estimate = empirical values; Z value = theoretical values
*Differences statistically significant
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Although this study has some limitations correlated with
small sample size, our results confirm that chronic fatigue is
one of the significant sequelae of TTand does not depend on a
lack of balance of (commonly evaluable) thyroid hormones.
Moreover, it seems to be independent of habits and comorbid-
ities that we did not consider as exclusion criteria. The reasons
for why this effect is correlated to total thyroidectomy and not
hemithyroidectomy are unexplained. It is possible that there is
an important role for unknown thyroid hormone imbalanced
in the appearance or worsening of chronic fatigue. In our
study, we excluded any patient with a TSH, fT3, or fT4 out-
side the normal respective ranges. However, there was no
evaluation concerning Bnonclassical^ thyroid hormones per-
formed. These hormones are produced by deiodination and
other biochemical pathways in peripheral tissues and the thy-
roid gland itself [44]. In particular, 3,5-diiodothyronine (T2)
showed intense activity in stimulating mitochondrial calcium
uptake and increasing mitochondrial dehydrogenase activity.
These changes can increase the resting metabolic rate (RMR)
and an intense and rapid stimulation of oxygen consumption
in experimental models. The pathways involved in the forma-
tion and clearance of the T2 are currently unknown [45–47].
Previous studies showed that T2 production from the T3 hor-
mone might be less prominent in hypothyroid patients treated
with L-T4 [48]. These data could suggest a possible involve-
ment of changes in T2 levels in PTCA if the decrease after TT
is proven. These findings were linked to other studies per-
formed in an experimental animal model that demonstrated
the effect of TT in altering the contractility of the diaphragm
muscle [49]. Thus, it appears reasonable that supplemental
treatment with desiccated thyroid extract (DTE) could im-
prove asthenia in patients with this symptom. One study re-
ported improved scores in a thyroid-specific questionnaire
given to a group of patients who had undergone treatment with
DTE [50]. Unfortunately, the DTE is not commonly available
and substances other than T3 and T4 are excluded by official
pharmacopeia [12].
Conclusion
Although the cause of the PTCA remains unexplained, the evi-
dence seems to be indisputable. We have not identified any risk
factors in this study, which suggests that the variable is indepen-
dent of several habits and diseases that might be considered as
risk factors. Additional clinical and experimental studies should
be performed to clarify the mechanisms involved in the initiation
and development of this underestimated sequelae.
TT was widely accepted as the treatment of choice for
thyroid cancer and for preventing recurrence in benign thyroid
diseases until recently. Moreover, many endocrinologists con-
sidered the follow-up after TT to be easy and safe.
The lack of an explanation for PTCA and the absence of
instruments for efficacious resistance suggest that it might by
valuable to reconsider of the indications of total thyroidecto-
my, which should be used only in the presence of strict and
highly selective criteria.
Compliance with ethical standards The Institutional Ethics Board
(Comitato Etico - Policlinico BP. Giaccone^ - Palermo) approved the
present study that has been performed in accordance with the ethical
standards of the 1964 Helsinki declaration. Informed consent was obtain-
ed from patients acting as subjects in our investigation.
No author has received funds for the implementation of this study.
Conflict of interest The authors declare that they have no conflict of
interest.
Fig. 2 The box-plot graphics show the increase of BFI in the first post-
operative period (6 months after surgery) in TT group and its decrease in
HTone. In the second post-operative period, (1 year after surgery) trends
in two groups do not change more. Both trends are statistically significant
(see Table 3)
1100 Langenbecks Arch Surg (2017) 402:1095–1102
References
1. Perzik S (1976) The place of total thyroidectomy in the manage-
ment of 909 patients with thyroid disease. Am J Surg 132(4):480–
483
2. Wheeler MH (1998) Total thyroidectomy for benign thyroid dis-
ease. Lancet 35:1526–1527
3. Liu Q, Djuricin C, Prinz RA (1998) Total thyroidectomy for benign
thyroid disease. Surgery 123:2–7
4. Bellantone R, Lompardi CP, Bossola M, Boscherini M, De Crea C,
Alesina P, Traini E, Princi P, Raffaelli M (2002) Total thyroidecto-
my for management of benign thyroid disease: review of 526 cases.
World J Surg 26:1468–1471
5. Marchesi M, Biffoni M, Faloci C, Biancari F, Campana FP (2002)
High rate of recurrence after lobectomy for solitary thyroid nodule.
Eur J Surg 168(7):397–400
6. Scerrino G, Salamone G, Airò FM, Ga R, Salamone S, Pompei G,
Buscemi G (2001) The multinodular non-toxic goitre: what a sur-
gery? Ann Ital Chir 72(6):647–652
7. Scerrino G, Cocorullo G, Paladino NC, Salamone G, Gulotta G
(2005) Quantification of the risk of relapses after loboistmusectomy
for benign thyroid nodules. Ann Ital Chir 76:321–329
8. Anjali M,Mayilvaganan S, Gyan C, Gaurav A, Amit A, AshokKV,
Saroj KM (2013) Quality of life (QoL) in patients with benign
thyroid goiters (pre- and post-thyroidectomy): a prospective study.
World J Surg. doi:10.1007/s00268-013-2133-3
9. Bianchi GP, Zaccheroni V, Solaroli E et al (2004)Health-related quality
of life in patients with thyroid disorders. Qual Life Res 13:45–54
10. McMillan C, Bradley C, Razvi S et al (2008) Evaluation of new
measures of the impact of hypothyroidism on quality of life and
symptoms: the ThyDQoL and ThySRQ. Value Health 11:285–294
11. Cramon P, Bonnema SJ, Bjorner JB, Ekholm O, Feldt-
Rasmussen U, Frendl DM, Groenvold M, Hegedus L,
Rasmussen AK, Watt T (2014) Quality of life in patients with
benign nontoxic goiter: impact of disease and treatment re-
sponse, and comparison with the general population. Thyroid
25(3):2015. doi:10.1089/thy.2014.0433
12. Rosato L, Pacini F, Panier SL, Mondini G, Ginardi A, Maggio M,
BoscoMC, Della Pepa C (2015) Post-thyroidectomy chronic asthe-
nia: self-deception or disease? Endocrine 48:615–620
13. WHO (2000) Obesity: preventing andmanaging the global epidem-
ic. Report of WHO consultation. WHO technical report series 894.
World Health Organization, Geneva
14. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hørding M,
Perrild H, Waldemar G (2004) Impaired health-related quality of
life in Grave’s disease. A prospective study Eur J Endocrinol 151:
549–555
15. Scerrino G, Morfino G, Paladino NC, Di Paola V, Amodio E,
Gulotta G, Bonventre S (2013) Does thyroid surgery for Graves'
disease improve health-related quality of life? Surg Today 43(12):
1398–1405
16. Raphael C, Briscoe C, Davies J, Whinnett ZI, Manisty C, Sutton R,
Mayet J, Francis DP (2007) Limitations of the New York Heart
Association functional classification system and self-reported walk-
ing distances in chronic heart failure. Heart 93:476–482
17. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS
(2001) Global strategy for the diagnosis, management, and preven-
tion of chronic obstructive pulmonary disease. NHLBI/WHO
Global initiative for chronic obstructive lung disease (GOLD).
Workshop summary. Am J Respir Crit Care Med 163:1256–1276
18. Durand F, Valla D (2008) Assessment of prognosis of cirrhosis.
Semin Liver Dis 28(1):110–122
19. Bauer C, Melamed ML, Hostetter TH (2008) Staging of chronic
kidney disease: time for a course correction. J Am Soc Nephrol 19:
844–846
20. American Diabetes Association (2010) Diagnosis and classification
of diabetes mellitus. Diabetes Care 33(Suppl. 1):s62–s69
21. Spitzer RL, Kroenke K, Williams JBW, Lowe B (2006) A brief
measure for assessing generalized anxiety disorder. Arch Intern
Med 166:1092–1097
22. Hamilton M (1960) Hamilton depression rating scale (HAM-D).
Hamilton, M. J Neurol Neurosurg Psychiatry 23:56–62
23. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA,
Wendt JK, Huber SL (1999) The rapid assessment of fatigue sever-
ity in cancer patients: use of the Brief Fatigue Inventory. Cancer
85(5):1186–1196
24. Huang X, Zhou W, Zhang Y (2015) Features of fatigue in patients
with early-stage non-small cells lung cancer. JResMedSci 20:268–
272
25. Cibas ES, Ali SZ (2009) The Bethesda System for reporting thyroid
cytopathology. AmJClin Path 132:658–665
26. Vassiliou I, Timpa A, Arkadopoulos N, Nikolakopoulos F,
Petropoulou T, Smyrniotis V (2013) Total thyroidectomy as the
single surgical option for benign and malignant thyroid disease: a
surgical challenge. Arch Med Sci 9(1):74–78
27. Agarwal G, Aggarwal V (2008) Is total thyroidectomy the surgical
procedure of choice for benign multinodular goiter? An evidence-
based review. World J Surg 32(7):1313–1324
28. Ozbas S, Kocak S, Aydintug S, Cakmak A, Demirkiran MA,
Wishart GC (2005) Comparison of the complications of subtotal,
near-total and total thyroidectomy in the surgical management of
multinodular goitre. Endocr J 52(2):199–205
29. Ritter K, Eifenbein D, Schneider DF, Chen H, Sippel RS (2015)
Hypoparathyroidism after total thyroidectomy: incidence and reso-
lution. J Surg Res 197(2):348–353
30. Nixon IJ, Simo R (2013) The neoplastic goitre. Curr Opin
Otolaryngol Head Neck Surg 21(2):143–149
31. Hauch A, Al QZ, Randolph G, Kandil E (2014) Total thyroidecto-
my is associated with an increased risk of complications for low-
and high-volume surgeons. Ann Surg Oncol 21(12):3844–3852
32. Bauer PS, Murray S, Clark N, Pontes DS, Sippel RS, Chen H
(2013) Unilateral thyroidectomy for the treatment of benign
multinodular goiter. JSurgRes 184(1):514–518
33. Vaisman S., Momesso D., Bulzico D.A., Pessoa C.H., da Cruz
M.D.G., Dias F., Corbo R., Vaisman M., Tuttle R.M. 2013:
Thyroid lobectomy is associated with excellent clinical outcomes
in properly selected differentiated thyroid cancer patients with pri-
mary tumors greater than 1 cm. J. Thyr. Res., ID 398194, 5 pages
34. Donatini G., Castagnet M., Desurmont T., Rudolph N., Othman D.,
Kraimps J.L. 2015: Partial thyroidectomy for papillary thyroid
microcarcinoma: is completion total thyroidectomy indicated?
World J. Surg., 6
35. SabaretnamM,Mishra A, Chand G, Agarwal G, Agarwal A, Verma
AK, Mishra SK (2012) Assessment of swallowing function impair-
ment in patients with benign goiters and impact of thyroidectomy: a
case-control study. World J Surg 36(6):1293–1299
36. Scerrino G, Inviati A, Di Giovanni S, Paladino NC, Di Paola V, Lo
RG, Almasio PL, Cupido F, Gulotta G, Bonventre S (2013)
Esophageal motility changes after thyroidectomy; possible associ-
ations with postoperative voice and swallowing disorders: prelimi-
nary results. Otolaryngol Head Neck Surg 148(6):926–932
37. Grover G, Saddler GP, Mihai R (2013) Morbidity after thyroid
surgery: the patient perspective. Laryngoscope 123(9):2319–2323
38. Schmitz-Winnenthal SH, Schimmack S, Lawrence B, Maier U,
Heidmann M, Buchler MW, von Frankenberg M (2011) Quality
of life is not influenced by the extent of surgery in patients with
benign goiter. Langenbeck’s Arch Surg 396(8):1157–1163
39. Bukvic BR, Zivaljevic VR, Sipetic SB, Diklic AD, Tausanovic
KM, Paunovic IR (2014) Improvement of quality of life in patients
with benign goiter after surgical treatment. Langenbeck’s Arch
Surg 399(6):755–764
Langenbecks Arch Surg (2017) 402:1095–1102 1101
40. Mishra A, SabaretnamM, Chand G, Agarwal G, Agarwal A, Verma
AK,Mishra SK (2013) Quality of life (QoL) in patients with benign
thyroid goiters (pre- and post-thyroidectomy): a prospective study.
World J Surg 37:2322–2329
41. Cramon P, Bonnema SJ, Bjorner JB, Ekholm O, Feldt-Rasmussen
U, Frendl DM, Groenvold M, Hegedüs L, Rasmussen AK, Watt T
(2015) Quality of life in patients with benign nontoxic goiter: im-
pact of disease and treatment response, and comparison with gen-
eral population. Thyroid 25(3):284–291
42. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC,
Hermann M (2011) Hashimoto's thyroiditis affects symptom load
and quality of life unrelated to hypothyroidism: a prospective case-
control study in women undergoing thyroidectomy for benign goi-
ter. Thyroid 21(2):161–167
43. Promberger R, HermannM, Pallikunnel SJ, Seemann R,MeuselM,
Ott J (2014) Quality of life after thyroid surgery in women with
benign euthyroid goiter: influencing factors including Hashimoto’s
thyroiditis. Amer J Surg 207:974–979
44. Senese R, Cioffi F, de Lange P, Goglia F, Lanni A (2014) Thyroid:
biological actions of Bnonclassical^ thyroid hormones. J Endocrinol
221:R1–R12
45. MorenoM, Lanni A, Lombardi A, Goglia F (1997) How the thyroid
controls metabolism in the rat: different roles for triiodothyroine
and diiodothyronines. J Physiol 505(2):529–538
46. Goglia F (2005) Biological effects of 3,5 - Diiodotironine (T2).
Biochemistry (Moskow) 70(2):164–172
47. Vaitkus JA, Farrar JS, Celi FS (2015) Thyroid hormone mediated
modulation of energy expenditure. Int J Mol Sci 16:16158–16175.
doi:10.3390/ijms160716158
48. Nishikawa M, Inada M, Naito K, Ishii H, Tanaka K, Mashio Y,
Imura I (1983) Serum concentrations of 3,3′-diiodothyronine, 3′-
5′-diiodothyronine and 3,5-diiodothyronine in altered thyroid
states. Endocrinol Japon 30(2):167–172
49. Adeniyi KO, Ogunkeye OO, Senok SS, Udoh FU (1992) The effect
of thyroidectomy and thyroxine on the reactivity of rat diaphragm
muscle to electrical stimulation in vitro. Acta Physiol Hung 79(4):
389–393
50. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MKM (2013)
Desiccated thyroid extract compared with levothyroxine in the
treatment of hypothyroidism: a randomized, double-blind, cross-
over study. J Clin Endocrinol Metab 98(5):1982–1990
1102 Langenbecks Arch Surg (2017) 402:1095–1102
